ARTICLE | Company News
Anaptys deal
March 8, 2010 8:00 AM UTC
AnaptysBio will use its somatic hypermutation (SHM) technology to generate antibodies against an undisclosed target for an undisclosed pharma. The pharma will have worldwide rights to develop and comm...